Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Storing blood and spinal fluid samples from people with memory concerns

Collects blood and optional spinal fluid from adults with memory problems for research.

Plain-language title generated from the registry record
Registry title: BioMIND Biospecimen Repository

Key facts

Where
London, CanadaSee the site

Where in Canada

  • Parkwood InstituteLondon, CanadaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Trial code
NCT07912736
Record updated
3 November 2026
Original description
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers.Read full original descriptionShow less

BioMIND Repository for the Collection and Storage of Biospecimens From Individuals With Memory Concerns

The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers.

Inclusion: Written informed consent obtained and documented, either from the participant or the substitute decision-maker; Must be a patient from the Aging Brain and Memory Clinic, Cognitive Neurology, or enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology; Geographic accessibility to the collection site; Ability to read, speak, and understand English.

Exclusion: Infectious disease cases such as prion diseases (e.g. Creutzfeldt-Jakob Disease), Human Immunodeficiency Virus, Ebola, or any other pathogen requiring containment above Biosafety Level 1; Age under 18 years (pediatric population).

ClinicalTrials.gov NCT07912736